Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

9

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor

6

Adrenergic receptor beta

6

Alpha-1a adrenergic receptor

6

Alpha-2a adrenergic receptor

6

Alpha-2b adrenergic receptor

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

9

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1950

6

1961

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cardiac arrest

6

Hypotension

6

Neurogenic orthostatic hypotension

6

Systemic inflammatory response syndrome

6

Major depressive episode without melancholia

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

9

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

6

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hazard, R.|Larde, R.

6

Burger, A.|Yost, W.L.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

EPA CompTox

9

FDA UNII

9

PUBCHEM

8

MERCK INDEX

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

2

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CARDIAC THERAPY

2

PSYCHOANALEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

2

ANTIDEPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Adrenergic and dopaminergic agents

2

Monoamine oxidase inhibitors, non-selective

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TRANYLCYPROMINE

3E3V44J4Z9

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Monoamine oxidase A

Monoamine oxidase B

Lysine-specific histone demethylase 1

Conditions:

Major depressive episode without melancholia

Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. Tranylcypromine has being marketed under original trade name Parnate, indicated for the treatment of major depressive episode without melancholia. Tranylcy...

promine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.

NOREPINEPHRINE

X4W3ENH1CV

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

TRANYLCYPROMINE HYDROCHLORIDE

7H4CZX4FYH

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Monoamine oxidase A

Monoamine oxidase B

Lysine-specific histone demethylase 1

Conditions:

Major depressive episode without melancholia

Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. Tranylcypromine has being marketed under original trade name Parnate, indicated for the treatment of major depressive episode without melancholia. Tranylcy...

promine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.

TRANYLCYPROMINE SULFATE

7ZAT6ES870

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1961

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Monoamine oxidase A

Monoamine oxidase B

Lysine-specific histone demethylase 1

Conditions:

Major depressive episode without melancholia

Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. Tranylcypromine has being marketed under original trade name Parnate, indicated for the treatment of major depressive episode without melancholia. Tranylcy...

promine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.

DROXIDOPA

J7A92W69L7

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

NORADRENALINE HYDROCHLORIDE

4W6461XR05

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

NOREPINEPHRINE BITARTRATE ANHYDROUS

ZW81GF408B

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

THREO-DIHYDROXYPHENYLSERINE

24A0V01WKS

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

Norepinephrine bitartrate

IFY5PE3ZRW

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1